Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03951012 · ClinicalTrials.gov registry record
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
A clinical trial, sponsored by Muhammad Furqan.
- Terminated
- Registry status
- 29
- Enrollment target
NCT03951012: Clinical Trial study, sponsored by Muhammad Furqan.
NCT03951012 is a clinical trial that was terminated before completion, run by Muhammad Furqan. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03951012 was terminated before completion, sponsored by Muhammad Furqan.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).
Primary Outcome
Treatment response will be measured every 2-3 months using iRECIST criteria.
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2023-09-08 |
Why NCT03951012 stopped before completion
NCT03951012 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT03951012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03951012 about?
NCT03951012 is a clinical study titled "Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy". Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03951012?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2019-04-15. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03951012?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT03951012?
This trial is sponsored by Muhammad Furqan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI